[4] Petrucci T, Blau I, Corradini P et al. Efficacy and safety of retreatment with bortezomib in patients with multiple myeloma: interim results from retrieve, a prospective international phase 2 study; 15 Congreso de la European Hematology Association 2010; 10 al 13 de junio; Barcelona, España. Abstr. 0377
[5] Dimopoulos M, Roddie H, Beksac M, et al. Randomized phase 2 trial of bortezomib-dexamethasone (VD) versus VD plus cyclophosphamide or lenalidomide in myeloma patients achieving stable disease after 4 cycles of VD as second-line treatment; 15 Congreso de la European Hematology Association 2010; 10 al 13 de junio; Barcelona, España. Abstr 0366
BEERSE, Bélgica, June 16, 2010 /PRNewswire/ --
Si desea más información contacte con: Jennifer Tear, directora de comunicaciones y asuntos públicos, teléfono: +32-14-60-26-38, móvil: +32-473-55-94-60, e-mail: JTear1@its.jnj.com
